ArticleFrontiers in immunology2025
Identification and validation of biomarkers related to centrosome replication in ulcerative colitis based on bulk transcriptome, single-cell RNA sequencing and experiments.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) is a complex chronic inflammatory disease. Centrosome amplification (CA) has been implicated in UC pathogenesis, but its mechanistic role remains unclear. This study aimed to investigate the relevance of centrosome amplification-related genes (CARGs) in UC progression. Methods: UC and control samples, along with CARGs, were obtained from public databases. Differential expression analysis identified differentially expressed genes (DEGs) between UC and controls. Candidate genes were selected by intersecting DEGs with CARGs. Biomarker identification employed 11 machine learning algorithms, receiver operating characteristic (ROC) analysis, and expression validation. Functional insights were gained through gene set enrichment analysis (GSEA), immune infiltration profiling, and clustering analysis. Cellular expression patterns of biomarkers were also examined. Finally, biomarker expression in colonic mucosal tissue was validated by RT-qPCR, Western blot, and Immunohistochemistry. Results: Six biomarkers-TEX11, SLC16A1, OVOL1, EDNRA, HEPACAM2, and SPIRE2-were identified. Enriched pathways associated with these genes included cell adhesion molecules (CAMs) and oxidative phosphorylation. Immune infiltration analysis revealed significant interactions between biomarkers and differential immune cells (DICs), such as neutrophils, in UC. Consensus clustering stratified UC samples into two clusters, with DICs including M0 macrophages showing significant correlations with biomarkers. Single-cell expression analysis highlighted undifferentiated and enteroendocrine cells as potentially key cell types in UC. Validation through animal and clinical experiments demonstrated downregulation of SLC16A1, OVOL1, TEX11, and HEPACAM2, alongside upregulation of EDNRA in colonic mucosa of UC compared to controls. Conclusion: Six CARGs-TEX11, SLC16A1, OVOL1, EDNRA, HEPACAM2, and SPIRE2-were identified as potential biomarkers with significant implications in UC pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.